4162 Stock Overview
A biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
PharmaEngine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$86.20 |
| 52 Week High | NT$115.00 |
| 52 Week Low | NT$74.80 |
| Beta | 0.67 |
| 1 Month Change | -10.40% |
| 3 Month Change | -1.37% |
| 1 Year Change | -15.07% |
| 3 Year Change | 35.96% |
| 5 Year Change | 28.47% |
| Change since IPO | 40.24% |
Recent News & Updates
Recent updates
Would PharmaEngine, Inc. (GTSM:4162) Be Valuable To Income Investors?
Mar 30
How Much Did PharmaEngine's(GTSM:4162) Shareholders Earn From Share Price Movements Over The Last Five Years?
Feb 18Is PharmaEngine, Inc.'s (GTSM:4162) Stock On A Downtrend As A Result Of Its Poor Financials?
Jan 14
We're Not Counting On PharmaEngine (GTSM:4162) To Sustain Its Statutory Profitability
Dec 10Shareholder Returns
| 4162 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -2.9% | -2.6% | -2.1% |
| 1Y | -15.1% | -0.8% | 25.6% |
Return vs Industry: 4162 underperformed the TW Biotechs industry which returned -0.8% over the past year.
Return vs Market: 4162 underperformed the TW Market which returned 25.6% over the past year.
Price Volatility
| 4162 volatility | |
|---|---|
| 4162 Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4162 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4162's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Hong-Ren Wang | www.pharmaengine.com |
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It offers ONIVYDE, a novel and stable encapsulated chemotherapy drug irinotecan for the treatment of metastatic pancreatic cancer and other indications of clinical development. The company is developing PEP07, a checkpoint kinase 1 inhibitor, which is in preclinical development stage for the treatment of hematologic cancers and solid cancers, such as acute myeloid leukemia and mantle cell lymphoma.
PharmaEngine, Inc. Fundamentals Summary
| 4162 fundamental statistics | |
|---|---|
| Market cap | NT$12.38b |
| Earnings (TTM) | NT$370.14m |
| Revenue (TTM) | NT$831.92m |
33.5x
P/E Ratio14.9x
P/S RatioIs 4162 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4162 income statement (TTM) | |
|---|---|
| Revenue | NT$831.92m |
| Cost of Revenue | NT$46.11m |
| Gross Profit | NT$785.81m |
| Other Expenses | NT$415.68m |
| Earnings | NT$370.14m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.58 |
| Gross Margin | 94.46% |
| Net Profit Margin | 44.49% |
| Debt/Equity Ratio | 0% |
How did 4162 perform over the long term?
See historical performance and comparisonDividends
1.7%
Current Dividend Yield58%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 08:18 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PharmaEngine, Inc. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Weiyu Li | Capital Securities Corporation |
| Jianzheng Wu | Capital Securities Corporation |
| Jerry Su | Credit Suisse |